{"id":61223,"date":"2026-03-25T13:38:14","date_gmt":"2026-03-25T05:38:14","guid":{"rendered":"https:\/\/flcube.com\/?p=61223"},"modified":"2026-03-25T13:38:15","modified_gmt":"2026-03-25T05:38:15","slug":"bayer-regenerons-eylea-hd-wins-japan-approval-for-rvo-third-indication-nod-with-extended-dosing-demonstrates-3-fewer-injections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61223","title":{"rendered":"Bayer\/Regeneron&#8217;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections"},"content":{"rendered":"\n<p><strong>Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW)<\/strong> has approved <strong>Eylea HD (aflibercept) injection 8 mg<\/strong> for <strong>visual impairment due to macular edema secondary to retinal vein occlusion (RVO)<\/strong> \u2013 marking the <strong>third indication nod in Japan<\/strong> for the high\u2011dose formulation and validating <strong>extended dosing intervals<\/strong> with patients receiving <strong>on average three fewer injections<\/strong> through week 64 vs. standard 2 mg dosing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>MHLW (Ministry of Health, Labour and Welfare, Japan)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Eylea HD (aflibercept) injection 8 mg<\/td><\/tr><tr><td><strong>Companies<\/strong><\/td><td>Bayer AG + Regeneron Pharmaceuticals, Inc.<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td><strong>Macular edema secondary to RVO<\/strong> (branch, central, hemi\u2011retinal vein occlusion)<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Phase III QUASAR study<\/td><\/tr><tr><td><strong>Japan Indication Count<\/strong><\/td><td><strong>Third<\/strong> (nAMD, DME, RVO)<\/td><\/tr><tr><td><strong>Recent EU Approval<\/strong><\/td><td>RVO indication approved (reference for Japan submission)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-quasar-phase-iii\">Clinical Evidence \u2013 QUASAR Phase III<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Eylea HD 8 mg<\/th><th>Eylea 2 mg<\/th><th>Clinical Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Visual Acuity Maintenance<\/strong><\/td><td>Maintained<\/td><td>Maintained<\/td><td>Non\u2011inferior efficacy<\/td><\/tr><tr><td><strong>Total Injections (Week 64)<\/strong><\/td><td><strong>8.5<\/strong><\/td><td><strong>11.7<\/strong><\/td><td><strong>3 fewer injections<\/strong> \u2013 reduced treatment burden<\/td><\/tr><tr><td><strong>\u22654\u2011Month Treatment Interval<\/strong><\/td><td><strong>&gt;60%<\/strong> of patients<\/td><td>\u2013<\/td><td>Extended dosing sustainability<\/td><\/tr><tr><td><strong>5\u2011Month Interval Achievement<\/strong><\/td><td><strong>40%<\/strong> of patients<\/td><td>\u2013<\/td><td>Maximum convenience segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dosing Regimen:<\/strong> Three initial monthly doses \u2192 extended interval maintenance<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-amp-commercial-footprint\">Global Regulatory &amp; Commercial Footprint<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>RVO Status<\/th><th>Other Approved Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>Japan<\/strong><\/td><td><strong>New \u2013 March 2026<\/strong><\/td><td>nAMD, DME<\/td><\/tr><tr><td><strong>European Union<\/strong><\/td><td>Recently approved<\/td><td>nAMD, DME<\/td><\/tr><tr><td><strong>Global Markets<\/strong><\/td><td><strong>&gt;60 markets<\/strong> approved<\/td><td>nAMD, DME<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Territory<\/th><th>Bayer Rights<\/th><th>Regeneron Rights<\/th><th>Profit Sharing<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>\u2013<\/td><td><strong>Exclusive<\/strong> (Eylea 2 mg + Eylea HD)<\/td><td>Regeneron retains US profits<\/td><\/tr><tr><td><strong>Outside US (ex\u2011US)<\/strong><\/td><td><strong>Exclusive marketing rights<\/strong><\/td><td>\u2013<\/td><td><strong>Equal 50\/50 profit share<\/strong> on Eylea 2 mg + Eylea 8 mg sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RVO Market Dynamics:<\/strong> Retinal vein occlusion affects <strong>~1.5 million patients annually<\/strong> globally; macular edema <strong>leading cause of vision loss<\/strong> in RVO; anti\u2011VEGF standard of care with <strong>treatment burden<\/strong> (monthly injections) major compliance challenge; Eylea HD&#8217;s <strong>extended interval<\/strong> (Q4\u20115 months vs. Q4\u20118 weeks standard) addresses <strong>unmet need for reduced injection frequency<\/strong>.<\/li>\n\n\n\n<li><strong>Eylea HD Differentiation:<\/strong> 8 mg high\u2011dose formulation enables <strong>sustained VEGF suppression<\/strong> supporting extended intervals; <strong>3 fewer injections<\/strong> over 64 weeks translates to <strong>~25% reduction<\/strong> in treatment burden; <strong>40% achieving 5\u2011month intervals<\/strong> positions for <strong>competitive advantage<\/strong> vs. Roche&#8217;s Vabysmo (faricimab, Q4\u201116 weeks) and Novartis&#8217;s investigational high\u2011dose therapies.<\/li>\n\n\n\n<li><strong>Japan Market Strategy:<\/strong> Third indication approval <strong>validates MHLW confidence<\/strong> in Eylea HD safety\/efficacy profile; <strong>RVO patient population<\/strong> (~50,000\u201180,000 annually in Japan) adds <strong>\u00a510\u201115 billion<\/strong> incremental revenue potential (2026\u20112028); <strong>physician preference<\/strong> for extended dosing in injection\u2011fatigued patients drives <strong>market share capture<\/strong> from standard\u2011dose Eylea and competitor products.<\/li>\n\n\n\n<li><strong>Bayer Ex\u2011US Commercial Execution:<\/strong> Bayer&#8217;s <strong>ophthalmology franchise strength<\/strong> (Europe, Asia\u2011Pacific, Latin America) leverages Eylea HD RVO approval for <strong>global rollout<\/strong>; <strong>50\/50 profit share<\/strong> with Regeneron maintains partnership alignment; <strong>EU + Japan + 60+ market approvals<\/strong> support <strong>US$800 million\u20111.2 billion<\/strong> annual Eylea HD ex\u2011US peak sales (2028\u20112030).<\/li>\n\n\n\n<li><strong>Competitive Response:<\/strong> Roche&#8217;s <strong>Vabysmo (faricimab)<\/strong> offers Q4\u201116 week dosing but <strong>no 8 mg equivalent<\/strong>; Novartis <strong>high\u2011dose brolucizumab<\/strong> limited by safety concerns; Eylea HD&#8217;s <strong>proven safety profile + extended interval<\/strong> may defend <strong>market leadership<\/strong> against bispecific and next\u2011gen VEGF inhibitors; <strong>price premium<\/strong> for HD formulation (~10\u201115% over 2 mg) justified by reduced injection burden.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market expansion timelines, competitive positioning, and revenue projections for Eylea HD in RVO and other indications. Actual results may differ due to competitive dynamics with Vabysmo and emerging therapies, reimbursement negotiations in Japan and EU markets, and long\u2011term safety data requirements for high\u2011dose anti\u2011VEGF therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61226,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,44,15,1426],"class_list":["post-61223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-ophthalmology","tag-product-approvals","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer\/Regeneron&#039;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61223\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer\/Regeneron&#039;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections\" \/>\n<meta property=\"og:description\" content=\"Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61223\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T05:38:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T05:38:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer\\\/Regeneron&#8217;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections\",\"datePublished\":\"2026-03-25T05:38:14+00:00\",\"dateModified\":\"2026-03-25T05:38:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223\"},\"wordCount\":567,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2504.webp\",\"keywords\":[\"Bayer\",\"Ophthalmology\",\"Product approvals\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61223#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61223\",\"name\":\"Bayer\\\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2504.webp\",\"datePublished\":\"2026-03-25T05:38:14+00:00\",\"dateModified\":\"2026-03-25T05:38:15+00:00\",\"description\":\"Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61223\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer\\\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61223#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer\\\/Regeneron&#8217;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections - Insight, China&#039;s Pharmaceutical Industry","description":"Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61223","og_locale":"en_US","og_type":"article","og_title":"Bayer\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections","og_description":"Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.","og_url":"https:\/\/flcube.com\/?p=61223","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-25T05:38:14+00:00","article_modified_time":"2026-03-25T05:38:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61223#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61223"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer\/Regeneron&#8217;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections","datePublished":"2026-03-25T05:38:14+00:00","dateModified":"2026-03-25T05:38:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61223"},"wordCount":567,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","keywords":["Bayer","Ophthalmology","Product approvals","Regeneron Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61223#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61223","url":"https:\/\/flcube.com\/?p=61223","name":"Bayer\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61223#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","datePublished":"2026-03-25T05:38:14+00:00","dateModified":"2026-03-25T05:38:15+00:00","description":"Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) \u2013 marking the third indication nod in Japan for the high\u2011dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61223#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61223"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61223#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","width":1080,"height":608,"caption":"Bayer\/Regeneron's Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61223#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer\/Regeneron&#8217;s Eylea HD Wins Japan Approval for RVO \u2013 Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61223"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61223\/revisions"}],"predecessor-version":[{"id":61227,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61223\/revisions\/61227"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61226"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}